Nu Skin: 50% Downside Is Possible In 2023
Despite re-openings in China, Nu Skin's operations remain exposed to cyclical risks. The company's net margins are poor, and earnings crash risk is...
395 Views
Nu Skin: Sell On The Pullback
Nu Skin's weak year-to-date performance is due to a culmination of factors that stem from both systemic and idiosyncratic events
217 Views
Video: Volition – executive interview
Volition is a multi-national epigenetics company developing simple, easy-to-use, cost-effective blood tests to help diagnose a range of cancers and...
585 Views